ES2112483T3 - 4-aril-4-hidroxi-tetrahidropiranos y 3-aril-3-hidroxi-tetrahidrofuranos como inhibidores de 5-lipoxigenasa. - Google Patents

4-aril-4-hidroxi-tetrahidropiranos y 3-aril-3-hidroxi-tetrahidrofuranos como inhibidores de 5-lipoxigenasa.

Info

Publication number
ES2112483T3
ES2112483T3 ES94303012T ES94303012T ES2112483T3 ES 2112483 T3 ES2112483 T3 ES 2112483T3 ES 94303012 T ES94303012 T ES 94303012T ES 94303012 T ES94303012 T ES 94303012T ES 2112483 T3 ES2112483 T3 ES 2112483T3
Authority
ES
Spain
Prior art keywords
hidroxi
aril
inhibitors
hydrogen
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94303012T
Other languages
English (en)
Inventor
Thomas Geoffrey Colerick Bird
Patrick Ple
Graham Charles Crawley
Michael Stewart Large
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca SAS
Syngenta Ltd
Original Assignee
Zeneca Pharma SA
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Pharma SA, Zeneca Ltd filed Critical Zeneca Pharma SA
Application granted granted Critical
Publication of ES2112483T3 publication Critical patent/ES2112483T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION CONCIERNE A DERIVADOS DE ETER DE LA FORMULA I, EN LA QUE Q1 ES UNA MITAD HETEROCICLICA BICICLICA DE 9 -, 10 -, O 11 MIEMBROS OPCIONALMENTE SUSTITUIDA QUE CONTIENEN UNO O DOS HETEROATOMOS DE NITROGENO Y QUE OPCIONALMENTE CONTIENE UN HETEROATOMO MAS SELECCIONADO DE ENTRE NITROGENO, OXIGENO Y AZUFRE; X ES OXI, CIANO, SULFINILO O SULFONILO; AR ES FENILENO, PIRIDINEDIILO, CIOFENEDIILO, FURANODIILO, CIAZOLEDIILO, OXAZOLEDIILO, CIADIAZOLEDIILO O OXADIAZOLEDIILO OPCIONALMENTE SUSTITUIDO; Y Q2 SE SELECCIONA DE ENTRE LOS GRUPOS DE LAS FORMULAS II Y III, EN LAS QUE R1 ES HIDROGENO, (25 ILO OPCIONALMENTE SUSTITUIDO; R2 ES (1 HIDROGENO O (1 AR UN GRUPO METILENO, VINILENO, ETILENO O TRIMEILENO; O UNA SAL CONSIGUIENTE FARMACEUTICAMENTE ACEPTABLE; PROCESO PARA SU PREPARACION; COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO COMO INHIBIDORES DE 5
ES94303012T 1993-04-29 1994-04-26 4-aril-4-hidroxi-tetrahidropiranos y 3-aril-3-hidroxi-tetrahidrofuranos como inhibidores de 5-lipoxigenasa. Expired - Lifetime ES2112483T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP93401120 1993-04-29
EP93401991 1993-08-02
EP94400190 1994-01-28

Publications (1)

Publication Number Publication Date
ES2112483T3 true ES2112483T3 (es) 1998-04-01

Family

ID=27235558

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94303012T Expired - Lifetime ES2112483T3 (es) 1993-04-29 1994-04-26 4-aril-4-hidroxi-tetrahidropiranos y 3-aril-3-hidroxi-tetrahidrofuranos como inhibidores de 5-lipoxigenasa.

Country Status (24)

Country Link
US (2) US5478842A (es)
EP (1) EP0623614B1 (es)
JP (1) JP3553127B2 (es)
KR (1) KR100358464B1 (es)
CN (1) CN1052002C (es)
AP (1) AP9400632A0 (es)
AT (1) ATE163417T1 (es)
AU (1) AU681886B2 (es)
CA (1) CA2121199C (es)
CZ (1) CZ280695A3 (es)
DE (1) DE69408593T2 (es)
DK (1) DK0623614T3 (es)
ES (1) ES2112483T3 (es)
FI (2) FI109123B (es)
GB (1) GB9408001D0 (es)
HK (1) HK1004777A1 (es)
HU (1) HU9502968D0 (es)
IL (1) IL109254A (es)
NO (1) NO309191B1 (es)
NZ (1) NZ266139A (es)
PL (1) PL311300A1 (es)
SK (1) SK134995A3 (es)
TW (1) TW252978B (es)
WO (1) WO1994025453A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3990972B2 (ja) * 2001-11-20 2007-10-17 有限会社 キック 血管再狭窄防止薬及び該防止薬がコーティングされた血管内埋め込み器具
SE0104274D0 (sv) * 2001-12-17 2001-12-17 Astrazeneca Ab Novel process
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
EP1978966A4 (en) 2006-01-23 2010-11-10 Amira Pharmaceuticals Inc TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
JP2010511632A (ja) 2006-11-30 2010-04-15 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼ活性化タンパク質インヒビターおよび一酸化窒素モジュレーターを含んでいる組成物および治療法
US10793515B2 (en) * 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
RU2624506C2 (ru) 2009-04-29 2017-07-04 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтические композиции, содержащие ера и сердечно-сосудистое средство, и способы их применения
EP3906925A1 (en) 2014-02-04 2021-11-10 Bioscience Pharma Partners, LLC Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system
TWI718146B (zh) 2015-05-04 2021-02-11 瑞典商阿斯特捷利康公司 新穎的5-脂氧合酶啟動蛋白（ｆｌａｐ）抑制劑
EA201990957A1 (ru) 2016-10-28 2019-09-30 Астразенека Аб Кристаллическая форма (1r,2r)-2-[4-(3-метил-1h-пиразол-5-ил)бензоил]-n-(4-оксо-4,5,6,7-тетрагидропиразоло[1,5-a]пиразин-3-ил)циклогексанкарбоксамида

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4794188A (en) * 1982-12-01 1988-12-27 Usv Pharmaceutical Corporation Certain unsymmetrical quinolinyl ethers having anti-inflammatory and anti-allergic activity
US4567184A (en) * 1982-12-01 1986-01-28 Usv Pharmaceutical Corporation Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or 1-hydroxy-hexane which are useful for treating inflammation and allergies
US4625034A (en) * 1985-02-04 1986-11-25 Usv Pharmaceutical Corp. 1,2-Dihydro; 1,2,3,4-tetrahydro; 5,8 dihydro; and 5,6,7,8-tetrahydroquinoline derivatives
US4725619A (en) * 1985-04-16 1988-02-16 Usv Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4728668A (en) * 1985-04-16 1988-03-01 Usv Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4631287A (en) * 1985-04-16 1986-12-23 Usv Pharmaceutical Corp. Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4868193A (en) * 1986-09-24 1989-09-19 Rorer Pharmaceutical Corporation Styryl tetrazoles and anti-allergic use thereof
GB8926981D0 (en) * 1988-12-23 1990-01-17 Ici Plc Heterocyclic derivatives
US5234950A (en) * 1988-12-23 1993-08-10 Imperial Chemical Industries Plc Tetrahydrofuran derivatives
US5202326A (en) * 1989-02-28 1993-04-13 Imperial Chemical Industries Plc Heterocyclic ethers
IE70521B1 (en) * 1989-02-28 1996-12-11 Zeneca Pharma Sa Heterocycles with inhibitory activity of 5-lipoxygenase
US5134148A (en) * 1989-02-28 1992-07-28 Imperial Chemical Industries Plc Heterocycles for use as inhibitors of leukotrienes
US5236919A (en) * 1989-02-28 1993-08-17 Imperial Chemical Industries Plc Quinoxalinyl derivatives suitable for use in leukotriene mediated disease
IE64358B1 (en) * 1989-07-18 1995-07-26 Ici Plc Diaryl ether heterocycles
GB9018134D0 (en) * 1989-09-29 1990-10-03 Ici Plc Heterocyclic derivatives
US5088927A (en) * 1990-06-18 1992-02-18 Lee Howard G Radio opaque plastics and process of making
IE911919A1 (en) * 1990-06-21 1992-01-01 Zeneca Ltd Bicyclic heterocyclic compounds
IE911853A1 (en) * 1990-06-21 1992-01-01 Ici Plc Heterocyclene derivatives
GB9113137D0 (en) * 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
IE913866A1 (en) * 1990-11-28 1992-06-03 Ici Plc Aryl derivatives
US5272173A (en) * 1990-11-28 1993-12-21 Imperial Chemical Industries Plc 5-lipoxygenase inhibitors
EP0501579A1 (en) * 1991-02-28 1992-09-02 Merck Frosst Canada Inc. Naphthalene lactones as inhibitors of leukotriene biosynthesis
EP0501578A1 (en) * 1991-02-28 1992-09-02 Merck Frosst Canada Inc. Pyranylphenyl hydroxyalkylnaphthoic acids as inhibitors of leukotriene biosynthesis
US5308852A (en) * 1992-06-29 1994-05-03 Merck Frosst Canada, Inc. Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis

Also Published As

Publication number Publication date
NO309191B1 (no) 2000-12-27
US5478842A (en) 1995-12-26
HK1004777A1 (en) 1998-12-04
AP9400632A0 (en) 1995-10-07
KR100358464B1 (ko) 2003-02-05
HU9502968D0 (en) 1995-12-28
DK0623614T3 (da) 1998-09-28
AU6721294A (en) 1994-11-21
EP0623614A1 (en) 1994-11-09
CN1121715A (zh) 1996-05-01
DE69408593T2 (de) 1998-07-16
CN1052002C (zh) 2000-05-03
SK134995A3 (en) 1996-07-03
ATE163417T1 (de) 1998-03-15
FI955165A0 (fi) 1995-10-27
DE69408593D1 (de) 1998-04-02
NO954321L (no) 1995-10-27
GB9408001D0 (en) 1994-06-15
US5512594A (en) 1996-04-30
FI20020270A (fi) 2002-02-11
TW252978B (en) 1995-08-01
NZ266139A (en) 1997-08-22
IL109254A0 (en) 1994-07-31
CZ280695A3 (en) 1996-01-17
NO954321D0 (no) 1995-10-27
IL109254A (en) 1999-03-12
CA2121199A1 (en) 1994-10-30
FI109123B (fi) 2002-05-31
FI955165A (fi) 1995-10-27
PL311300A1 (en) 1996-02-05
JPH0770114A (ja) 1995-03-14
AU681886B2 (en) 1997-09-11
CA2121199C (en) 2001-08-07
EP0623614B1 (en) 1998-02-25
WO1994025453A1 (en) 1994-11-10
JP3553127B2 (ja) 2004-08-11

Similar Documents

Publication Publication Date Title
ES2185665T3 (es) Derivados de benzofurano como antagonistas de taquicininas.
ES2169248T3 (es) Compuestos aromaticos y composiciones farmaceuticas que los contienen.
ES2112332T3 (es) Derivados de substitucion de oxigeno de productos de adicion de nucleofilo-oxido nitrico utilizados como promedicamentos donadores de oxido nitrico.
ES2100187T3 (es) Derivados de carboestirilos y composiciones farmaceuticas que los contienen.
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
ES2143238T3 (es) Derivados de 1-(piperidinil disustituido en posiciones 1,2)-piperazinas sustituidas en posicion 4.
DK0889876T3 (da) Meta-substituerede phenylensulfonamidderivater
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
ES2112483T3 (es) 4-aril-4-hidroxi-tetrahidropiranos y 3-aril-3-hidroxi-tetrahidrofuranos como inhibidores de 5-lipoxigenasa.
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
FI970317A0 (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
MX9300786A (es) Compuestos hipolipidaemicos.
AR009938A1 (es) Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos
DE69911935D1 (de) Granulatimide-derivate zur behandlung von krebs
FR2835526B1 (fr) Nouveaux composes, compositions les comprenant et leur utilisation pour favoriser la desquamation
AR001931A1 (es) Compuesto de 7-acilamino-3-iminometil (sustituido)cefalosporinas un proceso para su producción intermediarios en su producción una composición farmacéutica que contiene tales compuestos su utilizacióncomo compuestos farmacéuticos y un método para tratar enfermedades microbianas mediante administración de tales compuestos
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
ES2167021T3 (es) Derivados de acido 4-bifenil-4-hidroxibutirico sustituidos como inhibidores de metaloproteasa de matriz.
CO4290299A1 (es) Derivados de 1,5-benzodiazepina
ES2171911T3 (es) Poliaminas conformacionalmente restringidas y su uso como agentes antineoplasicos.
ES2188743T3 (es) Compuestos de acido pirrolidinilhidroxamico y procedimiento de produccion de los mismos.
ES2106936T5 (es) Derivados de carbazolona y procedimientos para su preparacion.
MX9204858A (es) Mejoras en derivados de 2-(piperazinoalquil)indol condensados en posiciones 1,7, asi como un procedimiento y productos intermedios para su preparacion y medicamentos que contienen estos compuestos.
PT94957A (pt) Processo para preparacao de composicoes farmaceuticas para tratamento da hipertrofia e hiperplasia cardiais e vasculares compreendendo um inibidor do enzima de conversao da angiotensina
ES2183492T3 (es) Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 623614

Country of ref document: ES